Information Provided By: 
Fly News Breaks for October 31, 2018
PFE, EXAS
Oct 31, 2018 | 07:59 EDT
Canaccord analyst Mark Massaro said the bull case for Exact Sciences (EXAS) remains intact after the company delivered another beat and raise quarterly result. The analyst believes the focus will now turn to how well the Pfizer (PFE) and Exact Sciences sales reps work together in Q4 and beyond. Massaro reiterated his Buy rating and $87 price target on Exact Sciences shares.
News For EXAS;PFE From the Last 2 Days
PFE
Apr 22, 2024 | 08:13 EDT
Pfizer announced that the European Commission, or EC, has granted marketing authorization for Emblaveo for the treatment of adult patients with complicated intra-abdominal infections, or cIAI, hospital-acquired pneumonia, or HAP, including ventilator-associated pneumonia, or VAP, and complicated urinary tract infections, or cUTI, including pyelonephritis. It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
